In short
PF-08653945 is an investigational medicine being studied for chronic weight management and related conditions. The only registered trial so far is a Phase 1 study in 57 adults with overweight or obesity, currently authorised but not yet recruiting. The trial measures how the medicine is taken up into the blood after a single injection under the skin.
PF-08653945 is an investigational substance being developed for chronic weight management and other weight-related co-morbidities. It has no marketing authorisation and has only reached Phase 1 clinical testing. The single registered trial is authorised but not yet recruiting participants.
Key points
- PF-08653945 is an investigational medicine with no marketing authorisation yet.
- It is being studied for chronic weight management and other weight-related co-morbidities.
- The only registered trial is Phase 1, the earliest stage of testing in humans.
- The trial plans to enrol 57 adults with overweight or obesity.
- The trial is currently authorised but not yet recruiting participants.
- The main goal is to measure how much of the medicine reaches the blood after a single subcutaneous injection.
What is PF-08653945?
PF-08653945 is an investigational medicine, meaning it has not yet been approved for use outside of clinical trials. The registered trial does not state the class of medicine it belongs to or its mechanism of action. It is being studied in the area of chronic weight management and other weight-related co-morbidities.
How does PF-08653945 work?
The registered trial record does not describe how PF-08653945 works in the body. The trial focuses on how the medicine is taken up into the blood, rather than on its effects on weight. No information about its molecular target or mechanism of action is available from the registry data.
Which conditions is it studied for?
The registered trial lists the following area of study:
- Chronic weight management and other weight-related co-morbidities — the trial enrols adults with overweight or obesity, with the aim of understanding how the medicine behaves in the body.
How is PF-08653945 given?
PF-08653945 is given as a subcutaneous injection, which means it is injected into the tissue just under the skin. The trial compares injections given in the thigh or upper arm with injections given in the abdomen. The dose used in the trial is not stated in the registry record.
What do the clinical trials show?
There is one registered clinical trial of PF-08653945. It is a Phase 1 trial, the earliest stage of testing in humans, which focuses on how the medicine is taken up into the blood rather than on whether it works for weight loss.
The trial plans to enrol 57 adults with overweight or obesity. Its status is "Authorised", meaning it has received regulatory approval to begin but is not yet recruiting participants.
The primary outcomes measured are AUCinf (or AUClast if data do not permit) and Cmax. These are measures of how much of the medicine reaches the bloodstream and how long it stays there: Cmax is the highest concentration reached in the blood after the injection, and AUC (area under the curve) is the total exposure to the medicine over time.
The trial assesses the relative bioavailability of a single dose given subcutaneously to the thigh or upper arm compared to the abdomen. Bioavailability means how much of the injected medicine actually reaches the bloodstream.
What side effects are known?
No information on side effects of PF-08653945 is available from the registry data or any other provided source.